Kerrisdale Advisers LLC Makes New $3.02 Million Investment in Zoetis Inc. $ZTS

Kerrisdale Advisers LLC bought a new position in Zoetis Inc. (NYSE:ZTS) in the second quarter, Holdings Channel.com reports. The firm bought 42,000 shares of the company’s stock, valued at approximately $3,018,000. Zoetis comprises about 0.8% of Kerrisdale Advisers LLC’s investment portfolio, making the stock its 27th biggest holding.

A number of other hedge funds also recently made changes to their positions in ZTS. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis in the 2nd quarter valued at approximately $25,000. Dunhill Financial LLC increased its holdings in shares of Zoetis by 519.3% during the second quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares in the last quarter. Prosperity Bancshares Inc acquired a new position in shares of Zoetis during the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis in the 1st quarter valued at $28,000. Finally, Root Financial Partners LLC boosted its holdings in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

ZTS stock opened at $77.45 on Monday. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a market cap of $32.00 billion, a price-to-earnings ratio of 12.76, a PEG ratio of 1.80 and a beta of 0.73. The company’s fifty day simple moving average is $75.57 and its 200 day simple moving average is $95.40. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $156.49.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ZTS shares. TD Cowen reduced their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday, August 25th. BNP Paribas Exane cut their price target on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Piper Sandler lowered their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Finally, Cantor Fitzgerald set a $94.00 price objective on shares of Zoetis in a report on Tuesday, August 25th. Eight analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $107.43.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.